GlassScriptPhysician profile
Vengamamba Polu
NPI 1982916342
$5,590.97
in general payments reported to CMS, 2019-2025
31 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $607 · 2021: $876 · 2022: $731 · 2023: $789 · 2024: $1,018 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,136 · Education: $90.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.95 |
| Education | $90.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $891.31 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $628.03 | 2019-2025 | |
| Novo Nordisk INC | $612.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.43 | 2020-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $437.54 | 2020-2025 | Farxiga, Brilinta |
| Abbott Laboratories | $431.50 | 2021-2025 | Proclaim, Freestyle Libre 2, Freestyle Libre 3 |
| Corcept Therapeutics | $402.86 | 2023-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $343.77 | 2022-2025 | |
| Mannkind Corporation | $259.00 | 2019-2025 | |
| Radius Health, INC. | $104.05 | 2023-2025 | Tymlos |
| Abbvie INC. | $97.97 | 2023-2025 | |
| Kyowa Kirin, INC. | $96.50 | 2023-2025 | Crysvita |
| Averitas Pharma INC. | $91.78 | 2023-2025 | Qutenza |
| Amgen INC. | $86.88 | 2021-2025 | Evenity, Tepezza, Prolia |
| Merck Sharp & Dohme LLC | $79.98 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $77.34 | 2024-2025 | Isturisa, Signifor Lar |
| Medtronic Minimed, INC. | $66.57 | 2019 | |
| Cequr Corporation | $66.35 | 2023-2025 | Cequr Simplicity |
| Amneal Pharmaceuticals LLC | $65.42 | 2024-2025 | Unithroid |
| Beta Bionics, INC. | $50.58 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Sequel Med Tech, LLC | $43.61 | 2025 | Twiist |
| Insulet Corporation | $34.00 | 2021-2023 | Omnipod |
| Neurocrine Biosciences, INC. | $26.21 | 2025 | |
| Dexcom, INC. | $25.53 | 2022-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $18.88 | 2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $14.91 | 2025 | Gvoke Hypopen |
| Tandem Diabetes Care, INC. | $13.73 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Nevro Corp. | $13.49 | 2024 | Senza |
| Janssen Pharmaceuticals, INC | $12.48 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.09 | 2021 | |
| Grt US Holding, INC. | $10.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vengamamba Polu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.